Personalized Medicines - Global Strategic Business Report

Description: This report analyzes the worldwide markets for Personalized Medicines in US$ Million by the following Product Segments: Targeted Therapeutics, and Tests & Lab Services. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World.

Annual estimates and forecasts are provided for the period 2011 through 2020. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.

The report profiles 85 companies including many key and niche players such as:

- Abbott Molecular, Inc.
- Affymetrix, Inc.
- AstraZeneca plc
- Bayer HealthCare Pharmaceuticals
- Beckman Coulter Genomics

Contents: I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
Personalized Medicine

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

Prelude
Developing Countries Drive Growth
Personalized Medicines Slowly Gaining Ground
Personalized Medicine and Its Impact on Patient Care
Table 1: Drug Ineffectiveness for Select Therapeutic Categories as a Percentage of Patient Population (includes corresponding Graph/Chart)
Is Emergence of Personalized Medicine Signaling the End of Blockbusters?
List of Select Approved Personalized Medicines

2. MARKET GROWTH DRIVERS AND RESTRAINTS

Growth Drivers in a Gist
Key Market Restraints
Increasing Incidence and Prevalence of CDDs: A Major Growth Driver
Ballooning Global Population Offers Significant Growth Opportunities
Table 2: Top 25 Countries Worldwide in Terms of Population: 2010 & 2013 (includes corresponding Graph/Chart)
Aging Global Population Drives Personalized Medicines
Table 3: Global Population Statistics for the 65+ Age Group (2012) (includes corresponding Graph/Chart)
Table 4: Over-65 Years Population as a % of Total Population (2010 & 2020P) (includes corresponding Graph/Chart)
Table 5: Elderly Population (65+ Years) as a % of Total Population (2000 & 2025) (includes corresponding Graph/Chart)
Table 6: Life Expectancy at Birth for Select Countries (2012) (includes corresponding Graph/Chart)
Table 7: Percentage of Population Aged 65 and Above in EU-27 Countries, the US and Japan (1960-2030)
(includes corresponding Graph/Chart)
Table 8: Life Expectancy Rates at Birth by Geographic Region (1990 & 2011) (includes corresponding
Graph/Chart)
Increasing Healthcare Spending in Emerging Markets
Table 9: Healthcare Spending as % of GDP in Select Countries (2011) (includes corresponding Graph/Chart)
Technological Advancements and Consumer Push to Drive Personalized Medicine
Economic Uncertainty Affects Spending on Healthcare Services

3. PERSONALIZED MEDICINE MARKET TRENDS & CHALLENGES

Changing Patients’ Trends Drive Personalized Medicine
Adverse Drug Reactions of Prescription Drugs Drive Personalized Medicine Market
List of Top 10 Drugs with Adverse Drug Reactions
Genomics to Dictate Advancement of Personalized Medicines
Investors’ Interest Personalized Medicines Gathers Steam
Differentiation
The Key Aspect of Personalized Medicines to Draw Investors
Growing Investments in Sequencing Segment Drives Personalized Medicines Market
Companion Diagnostics Make Way for Personalized Medicine
Select Popular Drugs with Companion Diagnostics
Biomarkers as Companion Diagnostics
Personalized Medicines Helps Reducing R&D Costs
Personalized Medicine
A Corporate Growth Strategy
Development Pipeline Reveals Promising Picture for Personalized Medicine
Advancements in Biomedical Imaging to Enhance Personalized Medicines
Increasing Use of Personalized Medicines Drives Genetic Testing
Genetic Testing: The Rapidly Growing Segment of Molecular Diagnostics Market
Next-Generation Sequencing
A Giant Leap in Genome Sequencing
Single Nucleotide Polymorphism (SNP)
Making Advancements in Personalized Medicine
Personalized Medicine Industry
Inundated with Data
Challenges for Personalized Medicine
Lack of Clinically Useful Diagnostic Tests
Growth Dampener
Economics of Personalized Medicine
Adoption of Personalized Medicines
A Peek into Developed and Developing Economies
Personalized Medicines Trigger Competition in the Market

4. ONCOLOGY: A MAJOR PERSONALIZED MEDICINE MARKET

Oncology
A Key Market for Personalized Medicine
Diagnosed Cases of Cancer on the Rise
Table 10: Global Cancer Incidence by Region: 2012 (includes corresponding Graph/Chart)
Table 11: Cancer Incidence in Developed Nations by Site: 2012 (includes corresponding Graph/Chart)
World Cancer Statistics: Incidence and Mortality Data
Table 12: World Cancer Incidence by Geographic Region and Gender (2012): Number of New Cancer Cases
Reported (in Thousands) for Asia-Oceania, Europe, North America, Latin America & the Caribbean, and Africa
(includes corresponding Graph/Chart)
Table 13: World Cancer Mortality by Geographic Region and Gender (2012): Number of Cancer-Related
Deaths (in Thousands) for Asia-Oceania, Europe, North America, Latin America & the Caribbean, and Africa
(includes corresponding Graph/Chart)
Table 14: New Cancer Cases in the World by Affected Site (2012) (in Thousands) (includes corresponding
Graph/Chart)
Table 15: Global Incidence of Common Cancers in Men (2012): Number of New Cases Reported in
Thousands for Lung & Bronchus, Prostate, Colorectal and Liver Cancers (includes corresponding
Graph/Chart)
Table 16: Global Incidence of Common Cancers in Women (2012): Number of New Cases Reported in
Thousands for Breast, Colorectal, Lung & Bronchus and Liver Cancers (includes corresponding Graph/Chart)
Table 17: Global Cancer Mortality in Men for Select Cancers (2012): Number of Deaths in Thousands for Lung & Bronchus, Liver, Colorectal and Prostate Cancers (includes corresponding Graph/Chart)
Table 18: Global Cancer Mortality in Women for Select Cancers (2012): Number of Deaths in Thousands for Breast, Lung & Bronchus, Colorectal and Liver (includes corresponding Graph/Chart)
Cancer Prone Sites based on Age
Growing Cancer Cases in Developing Countries Bodes Well for the Personalized Medicine Market
Growing Importance of Personalized Drugs for Cancer Treatment
Global Cancer Biomarkers Market to Exhibit Growth
Few FDA Approved Predictive Biomarkers by Disease Area
Challenges for Adoption of Personalized Medicine in Cancer Treatment

5. SELECT TECHNOLOGICAL ADVANCEMENTS

NanoVelcro Chip Device
Enhanced to Personalize Treatment for Prostate Cancer
Development of New Cancer Treatment Method for Personalized Cancer Therapy
Gene Therapy using a Pill for Treating Cancer
New Ways of Offering Personalized Cancer Treatments
Theranostic Imaging
Developed for Offering Personalized Cancer Medicine
New Personalized Treatment Approach Prolongs the Life of Lung Cancer Patients

6. PRODUCT OVERVIEW

Personalized Medicine
Benefits of Personalized Medicines
Few Applications of Personalized Medicine
Colorectal Cancer
Blood Clots
Breast Cancer
Diagnostics in Personalized Medicine
Genetic Tests
Companion Diagnostics
Genetic Testing
Types of Genetic Testing
Prenatal Diagnosis
Cancer Testing
Carrier Identification
Newborn Screening
Predictive Testing
Pre-Symptomatic Testing
Cytogenetic Tests
Table 19: Costs of Select Genetic Tests
Proteomics: A Critical Drug Discovery Tool
Proteomics and Genomics: A Comparison

7. PRODUCT INTRODUCTIONS AND APPROvals

NMTC Launches Expanded Personalized Medicine Panel Created on Luminex's xMAP Technology
Dako to Introduce New Antibody to Diagnose Breast Cancer
bioMérieux's New Generation VIDAS® 3 Obtains CE Marking
GSK’s Two New Single-Agent Oral Oncology Treatments Receive FDA Approval
Dako Obtains FDA Approval for Two Companion Diagnostic Assays for Genentech's Kadcyla
Genentech Receives FDA Approval for Kadcyla Drug
Dako’s FISH Assay for Cancer Diagnostics Obtains FDA Approval
Luminex Receives US FDA Approval for MAGPIX® Instrument with xTAG GPP
QIAGEN Obtains FDA Approval for Marketing therascreen® KRAS RGQ PCR Kit
Roche Gains Approval from EMA for PERJETA
OGT Unveils SureSeq™ Solid Tumor Panel Sequencing Service
Abbott Launches Hepatitis C Virus Genotyping Test
Luminex Obtains CE Marking for Neonatal Screening Systems
IRIS International Launches NADiA® ProsVue™ Prognostic Test for Cancer
Lab21 Launches Novel Companion Diagnostic Service for Lung Cancer
Lab21 to Offer FDA approved Companion Diagnostic Test
Rosetta Genomics Obtains Approval from New York State Department of Health for miRview® Lung Assay
Merck Serono Receives Approval for Erbitux® for use in Neck and Head Cancer
Affymetrix Obtains Approval from China's SFDA for GeneChip® System 3000 Dx v.2
Dako Obtains FDA Approval for Hercep Test™ and HERFISH pharma Dx™ kit
Roche Obtains Approval of Perjeta™ by USFDA
NeoGenomics Introduces NeoTYPE™ Prognostic Panel

8. RECENT INDUSTRY ACTIVITY

Cancer Genetics and Mayo Clinic Establish JV
QIAGEN and Eli Lilly Sign Master Collaboration Agreement
Ignyta Takes Over Actagene Oncology
Lab21 Divests Laboratory Business to Reedy Acquisitions
Mayo Clinic Enters into Strategic Partnership with Silicon Valley Biosystems
Bristol Myers Squibb to Collaborate with Adaptive Biotechnologies
Government of Québec Invests in Personalized Medicine Partnership for Cancer
Millennium Pharmaceuticals and Worldwide Innovative Network Consortium Ink Collaboration Agreement
Affymetrix and UK Biobank Ink Contract
Bayer and Seattle Genetics Enter into Novel ADC Collaboration
Lab21 Joins Hands with IntegraGen to Develop Novel Colorectal Cancer Diagnosis
MacroGen Estabishes MCL
INVENT and Heliant Co-Invest in Sanguine BioSciences
Dako and Eli Lilly Enter into Partnership for Companion Diagnostic Tests Development
Geisenger to Enter into an Alliance with Indivumed
Deloitte Takes Over Recombinant Data
Thermo Fisher Scientific Renews Partnership with bioMérieux
QIAGEN Sign Agreements to Acquire Global Rights for Two Biomarkers
Selventa to Build Disease Models for Johnson & Johnson
Quintiles Takes Over Expression Analysis
Mckesson Acquires CDS Oncology Assets from Proventys
Horizon Partners with H3 Biomedicine to Develop Target Groups for Cancer Drugs
Abbott to Collaborate with Merck for FISH-based Diagnostic Test Evaluation
Bayer and QIAGEN Sign Strategic Partnership for Companion Diagnostic Tests Development
Life Technologies Signs a License and Supply Contract with VelaDx
IDBS Announces Deployment of ORIS by King's Health Partners
PGXL Laboratories Inks Multi-Year Distribution Partnership Agreement with Essential Molecular Testing
Uniqest Inks Memorandum of Understanding with Aquavit Pharmaceuticals
Agilent Technologies Acquires Dako
IRIS International Signs Merger Agreement with Danaher
Lab21 and BD Diagnostics Sign Collaboration Agreement
Lab21 Inks Partnership Agreement with a Major Pharmaceutical Company
Lab21 Signs Partnership Agreement with Leading IVD Company
Lab21 and ITOR Establish Clinical Genomics Center
Lab21 Takes over PCR Technology
PerkinElmer and MacroGen Enter into Agreement
NeoGenomics and Health Discovery Ink Exclusive Agreement for Global Licensing
QIAGEN Inks Agreement with Lepu Medical
QIAGEN Inks Agreement with Bio-X Center

9. FOCUS ON SELECT PLAYERS

Abbott Molecular, Inc. (US)
Affymetrix, Inc. (US)
AstraZeneca plc (UK)
Bayer HealthCare Pharmaceuticals (Germany)
Beckman Coulter Genomics (US)
bioMérieux SA (France)
Clariant, Inc. (US)
Dako Denmark A/S (Denmark)
F. Hoffmann-La Roche Ltd. (Switzerland)
GlaxoSmithKline plc. (UK)
Hologic, Inc. (US)
10. GLOBAL MARKET PERSPECTIVE

Table 20: World Recent Past, Current and Future Analysis for Personalized Medicines by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2020 (includes corresponding Graph/Chart)
Table 21: World 15-Year Perspective for Personalized Medicines by Geographic Region
Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2011, 2014 and 2020 (includes corresponding Graph/Chart)
Table 22: World Recent Past, Current and Future Analysis for Targeted Therapeutics by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2020 (includes corresponding Graph/Chart)
Table 23: World 15-Year Perspective for Targeted Therapeutics by Geographic Region
Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2011, 2014 and 2020 (includes corresponding Graph/Chart)
Table 24: World Recent Past, Current and Future Analysis for Tests & Lab Services for Personalized Medicine by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2020 (includes corresponding Graph/Chart)
Table 25: World 15-Year Perspective for Tests & Lab Services for Personalized Medicine by Geographic Region
Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2011, 2014 and 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

A. Market Analysis
   Outlook
   US Individualized Medicine Market to Witness Significant Growth
   Companies and Investors Bullish on Personalized Medicine Market in the US
   Government Agencies Push for Personalized Medicines
   Personalized Medicine Regulations in the FDA
   Changing for the Better
   Challenges for FDA in Approving Personalized Drugs
   Increasing Burden of Chronic Diseases Drives Focus onto Personalized Treatment
   Companion Diagnostic Market in the US
   Number of Companion Diagnostics under Development Keeps Soaring
   Direct-to-Consumer Testing
   A Growing Market
   Cancer Statistics in the US
   Table 26: New Cancer Cases by Gender and Affected Site in the US (2013)
   Personalized Medicine Creating Opportunities for Diagnostics Testing Services
   Molecular Diagnostics: Promising Growth Opportunities
   Genetic and Genomic Clinical Lab Testing Market: Promising Prospects
   Product Launches/ Approvals
   Strategic Corporate Developments
   Select Players

B. Market Analytics
   Table 27: The US Recent Past, Current and Future Analysis for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2020 (includes corresponding Graph/Chart)
   Table 28: The US 15-Year Perspective for Personalized Medicines by Segment
   Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2014 and 2020 (includes corresponding Graph/Chart)

2. CANADA
A. Market Analysis

Outlook

Rising Incidence of Chronic Diseases Spurs Need for Personalized Medicines

Table 29: New Cancer Cases in Canada by Gender and Affected Site (2012) (includes corresponding Graph/Chart)

Table 30: New Cancer Cases in Canada by Province (2012) (includes corresponding Graph/Chart)

Table 31: New Cancer Cases in Canada by Age Group and Gender (2012) (includes corresponding Graph/Chart)

Strategic Corporate Development

B. Market Analytics

Table 32: Canadian Recent Past, Current and Future Analysis for Personalized Medicines by Segment

Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2020 (includes corresponding Graph/Chart)

Table 33: Canadian 15-Year Perspective for Personalized Medicines by Segment

Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2014 and 2020 (includes corresponding Graph/Chart)

3. JAPAN

A. Market Analysis

Outlook

Demographics Drive Market Growth

Table 34: Percentage Breakdown of Japanese Population by Age Group (2012) (includes corresponding Graph/Chart)

Table 35: Over 65 Years Population in Japan (1950-2010) (includes corresponding Graph/Chart)

Product Approval

B. Market Analytics

Table 36: Japanese Recent Past, Current and Future Analysis for Personalized Medicines by Segment

Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2020 (includes corresponding Graph/Chart)

Table 37: Japanese 15-Year Perspective for Personalized Medicines by Segment

Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2014 and 2020 (includes corresponding Graph/Chart)

4. EUROPE

A. Market Analysis

Outlook

European Personalized Medicine Market to Exhibit Robust Growth

Debt Crisis in Europe Affects Healthcare Industry

European Healthcare System: In a State of Transition?

Aging Population to Drive Demand for Personalized Medicines

Table 38: Population Breakup by Age Group for Select European Countries: 2012 (As a % of Total Population) (includes corresponding Graph/Chart)

Insight into Molecular Diagnostics Markets in Europe

Table 39: Molecular Diagnostics Tests: Percentage Share Breakdown by Function (includes corresponding Graph/Chart)

Regulatory Scenario in Europe for Companion Diagnostics

Companion Diagnostics: Select European Players with Strong Biomarker Pipeline

The Need for Improving Reimbursement Policies

Product Approvals/Launches

B. Market Analytics

Table 40: European Recent Past, Current and Future Analysis for Personalized Medicines by Geographic Region

France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2020 (includes corresponding Graph/Chart)

Table 41: European 15-Year Perspective for Personalized Medicines by Geographic Region

Percentage Breakdown of Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2011, 2014 and 2020 (includes corresponding Graph/Chart)

Table 42: European Recent Past, Current and Future Analysis for Personalized Medicines by Segment

Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2020 (includes corresponding Graph/Chart)
Table 43: European 15-Year Perspective for Personalized Medicines by Segment
Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2014 and 2020 (includes corresponding Graph/Chart)

4a. FRANCE
A. Market Analysis
Outlook
Biomérieux Sa
A Key Player
B. Market Analytics

Table 44: French Recent Past, Current and Future Analysis for Personalized Medicines by Segment
Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2020 (includes corresponding Graph/Chart)

Table 45: French 15-Year Perspective for Personalized Medicines by Segment
Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2014 and 2020 (includes corresponding Graph/Chart)

4b. GERMANY
A. Market Analysis
Outlook
Market Overview
Strategic Corporate Development
Bayer Healthcare Pharmaceuticals
A Key Player
B. Market Analytics

Table 46: German Recent Past, Current and Future Analysis for Personalized Medicines by Segment
Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2020 (includes corresponding Graph/Chart)

Table 47: German 15-Year Perspective for Personalized Medicines by Segment
Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2014 and 2020 (includes corresponding Graph/Chart)

4c. ITALY
Market Analysis
Table 48: Italian Recent Past, Current and Future Analysis for Personalized Medicines by Segment
Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2020 (includes corresponding Graph/Chart)

Table 49: Italian 15-Year Perspective for Personalized Medicines by Segment
Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2014 and 2020 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM
A. Market Analysis
Outlook
Initiatives Supporting the Personalized Medicine Market
Product Approvals/Launches
Strategic Corporate Developments
Select Players
B. Market Analytics

Table 50: The UK Recent Past, Current and Future Analysis for Personalized Medicines by Segment
Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2020 (includes corresponding Graph/Chart)

Table 51: The UK 15-Year Perspective for Personalized Medicines by Segment
Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2014 and 2020 (includes corresponding Graph/Chart)

4e. REST OF EUROPE
A. Market Analysis
Outlook
Spain
Poised to become a Reckoning Force in Personalized Medicines
Strategic Corporate Development
Select Players
B. Market Analytics

Table 52: Rest of Europe Recent Past, Current and Future Analysis for Personalized Medicines by Segment
Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2020 (includes corresponding Graph/Chart)

Table 53: Rest of Europe 15-Year Perspective for Personalized Medicines by Segment
Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2014 and 2020 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

A. Market Analysis
Outlook
Healthcare Spending in Asia-Pacific: On the Rise
China and India: Two Fast-Growing Markets
Focus on Select Regions
India
Growing Investments in Pharmacogenomics Research Drives Personalized Medicine in India
China
Government Support Drives Personalized Medicine Market in China
Product Launch
Strategic Corporate Developments
Macrogen, Inc. (Korea)
A Key Player
B. Market Analytics
Table 54: Asia-Pacific Recent Past, Current and Future Analysis for Personalized Medicines by Segment
Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2020 (includes corresponding Graph/Chart)
Table 55: Asia-Pacific 15-Year Perspective for Personalized Medicines by Segment
Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2014 and 2020 (includes corresponding Graph/Chart)

6. REST OF WORLD

A. Market Analysis
Outlook
Rosetta Genomics Ltd (Israel)
A Key Player
B. Market Analytics
Table 56: Rest of World Recent Past, Current and Future Analysis for Personalized Medicines by Segment
Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2020 (includes corresponding Graph/Chart)
Table 57: Rest of World 15-Year Perspective for Personalized Medicines by Segment
Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2014 and 2020 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 85 (including Divisions/Subsidiaries 93)
The United States (64)
Canada (2)
Japan (1)
Europe (20)
France (5)
Germany (5)
The United Kingdom (6)
Rest of Europe (6)
Asia-Pacific (Excluding Japan) (3)
Latin America (1)
Middle East (2)

Ordering:
Order Online - http://www.researchandmarkets.com/reports/2832327/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Personalized Medicines - Global Strategic Business Report
Web Address: http://www.researchandmarkets.com/reports/2832327/
Office Code: SCH3W9L1

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 4950</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users</td>
<td></td>
<td>USD 6930</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 10 Users</td>
<td></td>
<td>USD 9405</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 15 Users</td>
<td></td>
<td>USD 11880</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp